AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2337559 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined lidocaine nerve block with halothane general anaesthesia
Number of subjects: 50
Study 2337559 — intervention group
Group type: COMPARATOR
Intervention: Halothane general anaesthesia alone
Number of subjects: 50
Study 6932209 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg intravaginal PG F2 alpha
Number of subjects: 83
Study 6932209 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxytocin
Number of subjects: 83
Study 31821059 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:80,000 epinephrine
Number of subjects: 118
Study 31821059 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine with 1:200,000 epinephrine
Number of subjects: 118
Study 31021884 — intervention group
Group type: EXPERIMENTAL
Intervention: Scenario plus video
Number of subjects: 36
Study 31021884 — intervention group
Group type: EXPERIMENTAL
Intervention: Scenario
Number of subjects: 36
Study 31021884 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-assessment
Number of subjects: 36
Study 31021884 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up stage at 4-week later
Number of subjects: 36
Study 31021884 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 27919609 — intervention group
Group type: EXPERIMENTAL
Intervention: Footplate Neuromuscular Electrical Stimulation Device (REVITIVE)
Number of subjects: 22
Study 27919609 — intervention group
Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 22
Study 25676084 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced external counterpulsation (EECP) therapy
Number of subjects: 17
Study 25676084 — intervention group
Group type: COMPARATOR
Intervention: Sham-EECP
Number of subjects: 17
Study 23591401 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib 400mg BID
Number of subjects: 246
Study 23591401 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246
Study 21675554 — intervention group
Group type: EXPERIMENTAL
Intervention: Correct information group
Number of subjects: 43
Study 21675554 — intervention group
Group type: EXPERIMENTAL
Intervention: Misleading information group
Number of subjects: 43
Study 21675554 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional information)
Number of subjects: 43
Study 19432985 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS treatment
Number of subjects: 10
Study 19432985 — intervention group
Group type: EXPERIMENTAL
Intervention: rhAPC treatment
Number of subjects: 10
Study 19432985 — intervention group
Group type: COMPARATOR
Intervention: Saline treatment
Number of subjects: 10
Study 16704587 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane-nitrous oxide anaesthesia
Number of subjects: 48
Study 16704587 — intervention group
Group type: COMPARATOR
Intervention: Control group (no anaesthesia)
Number of subjects: 48
Study 14695390 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed duration of contrast material injection for 25 seconds (group A)
Number of subjects: 199
Study 14695390 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed duration of contrast material injection for 35 seconds (group B)
Number of subjects: 199
Study 14695390 — intervention group
Group type: COMPARATOR
Intervention: Fixed injection rate of 4.0 mL/sec (group C)
Number of subjects: 199
Study 11720401 — intervention group
Group type: EXPERIMENTAL
Intervention: Typically prepared pureed peach
Number of subjects: 30
Study 11720401 — intervention group
Group type: EXPERIMENTAL
Intervention: Pureed peach with a thickening agent added
Number of subjects: 30
Study 11720401 — intervention group
Group type: EXPERIMENTAL
Intervention: Pureed peach with a thickening agent added and molded to look like peach slices
Number of subjects: 30
Study 11720401 — intervention group
Group type: EXPERIMENTAL
Intervention: Molded peach
Number of subjects: 30
Study 11720401 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall liking, liking of taste, texture, and appearance
Number of subjects: 30
Study 9405908 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study 9405908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8433117 — intervention group
Group type: EXPERIMENTAL
Intervention: Nine different presentations of breast cancer health descriptions
Number of subjects: 180
Study 8433117 — intervention group
Group type: EXPERIMENTAL
Intervention: Descriptions written in the third person with different wording regarding 'cancer'
Number of subjects: 180
Study 2889416 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg orally every 8 hours
Number of subjects: 45
Study 29449127 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel alone
Number of subjects: 28
Study 29449127 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel with PPIs (pantoprazole, omeprazole, rabeprazole, esomeprazole, lansoprazole, dexlansoprazole)
Number of subjects: 28
Study 26683394 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Zone III REBOA technique with ultrasonography guidance (Group A)
Number of subjects: 20
Study 26683394 — intervention group
Group type: COMPARATOR
Intervention: Standard measuring length of catheter insertion technique (Group B)
Number of subjects: 20
Study 24094879 — intervention group
Group type: COMPARATOR
Intervention: NCPAP range of 4‐6 cmH2O (low NCPAP)
Number of subjects: 93
Study 24094879 — intervention group
Group type: EXPERIMENTAL
Intervention: NCPAP range of 7‐9 cmH2O (high NCPAP)
Number of subjects: 93
Study 22882399 — intervention group
Group type: EXPERIMENTAL
Intervention: Guaranteed methadone treatment admission upon release
Number of subjects: 211
Study 22882399 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone in prison and guaranteed continuation of methadone upon release
Number of subjects: 211
Study 22882399 — intervention group
Group type: COMPARATOR
Intervention: Passive referral to substance abuse treatment upon release
Number of subjects: 211
Study 22882399 — intervention group
Group type: COMPARATOR
Intervention: Counseling in prison without methadone
Number of subjects: 211
Study 20173643 — intervention group
Group type: EXPERIMENTAL
Intervention: Metamizol 1 g
Number of subjects: 80
Study 20173643 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 1 g
Number of subjects: 80
Study 20173643 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam 8 mg
Number of subjects: 80
Study 20173643 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline 0.9% (placebo)
Number of subjects: 80
Study 18728103 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl (75, 100, 150, or 200 microg)
Number of subjects: 0
Study 18728103 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fentanyl (75, 100, 150, or 200 microg)
Number of subjects: 0
Study 18728103 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl
Number of subjects: 0
Study 15192463 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc‐99m‐labeled anti‐D IgG opsonized autologous RBC scintigraphy (RIS)
Number of subjects: 45
Study 15192463 — intervention group
Group type: COMPARATOR
Intervention: Tc‐99m heat‐denatured RBC spleen scintigraphy (HDRS)
Number of subjects: 45
Study 11124351 — intervention group
Group type: EXPERIMENTAL
Intervention: Framing of the question and structure of the problem to activate intuitive principles based on subset relations
Number of subjects: 0
Study 11124351 — intervention group
Group type: COMPARATOR
Intervention: Standard framing of probability and frequency problems
Number of subjects: 0
Study 9603591 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 12078
Study 9603591 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 12078
Study 9603591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12078
Study 9603591 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg
Number of subjects: 12078
Study 9603591 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 1 mg
Number of subjects: 12078
Study 7857040 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics
Number of subjects: 106
Study 7857040 — intervention group
Group type: COMPARATOR
Intervention: Control (no prophylactic antibiotics)
Number of subjects: 106
Study 2527940 — intervention group
Group type: EXPERIMENTAL
Intervention: Hevac‐B‐Pasteur
Number of subjects: 72
Study 2527940 — intervention group
Group type: COMPARATOR
Intervention: H‐B‐Vax I
Number of subjects: 72
Study 2527940 — intervention group
Group type: COMPARATOR
Intervention: Engerix B
Number of subjects: 72
Study 738078 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined preparation of 40 mg frusemide and 600 mg slow-release potassium chloride
Number of subjects: 10
Study 738078 — intervention group
Group type: COMPARATOR
Intervention: Separate tablets of 40 mg frusemide and 600 mg potassium chloride
Number of subjects: 10
Study 31456474 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Recovery (AR)
Number of subjects: 15
Study 31456474 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Water Immersion (CWI)
Number of subjects: 15
Study 31456474 — intervention group
Group type: COMPARATOR
Intervention: Static Stretching (SS)
Number of subjects: 15
Study 30753213 — intervention group
Group type: EXPERIMENTAL
Intervention: Activate intervention
Number of subjects: 67
Study 29137091 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer lactate solution (RL)
Number of subjects: 36
Study 29137091 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylated gelatin injection (Gel)
Number of subjects: 36
Study 29137091 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline hydroxyethyl starch 40 injection (HS)
Number of subjects: 36
Study 29137091 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 36
Study 29137091 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer lactate solution (RL) and Succinylated gelatin injection (Gel)
Number of subjects: 36
Study 25620547 — intervention group
Group type: EXPERIMENTAL
Intervention: Tangerine tomato juice (10 mg lycopene, 94% cis)
Number of subjects: 11
Study 25620547 — intervention group
Group type: COMPARATOR
Intervention: Red tomato juice (10 mg lycopene, 10% cis)
Number of subjects: 11
Study 23512550 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion
Number of subjects: 84
Study 23512550 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 84
Study 23512550 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 84
Study 21896765 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory language exposure
Number of subjects: 1
Study 20306936 — intervention group
Group type: EXPERIMENTAL
Intervention: Forgiveness education intervention
Number of subjects: 32
Study 20306936 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 16958569 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS MPH once daily (n = 32)
Number of subjects: 64
Study 16958569 — intervention group
Group type: COMPARATOR
Intervention: IR MPH three times daily (n = 32)
Number of subjects: 64
Study 15151265 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 12.5 mg/day
Number of subjects: 24
Study 15151265 — intervention group
Group type: COMPARATOR
Intervention: Ramipril 1.25 mg/day
Number of subjects: 24
Study 15151265 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (after washout period)
Number of subjects: 24
Study 15151265 — intervention group
Group type: COMPARATOR
Intervention: Ramipril (after washout period)
Number of subjects: 24
Study 15151265 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (during dialysis)
Number of subjects: 24
Study 11472790 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 130
Study 11472790 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT) + fluoxetine
Number of subjects: 130
Study 11472790 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative REMs
Number of subjects: 130
Study 9144122 — intervention group
Group type: EXPERIMENTAL
Intervention: L. reuteri
Number of subjects: 40
Study 9144122 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 7698722 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta-sleep-inducing peptide (DSIP) 25 nmol/kg
Number of subjects: 8
Study 7698722 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 8
Study 7698722 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline (0.51 M NaCl)
Number of subjects: 8
Study 7698722 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthostatic test (standing upright for 20 min)
Number of subjects: 8
Study 2951260 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenflumizole 10 mg b.i.d. for four days followed by 10 mg daily for six days (Group I)
Number of subjects: 10
Study 2951260 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenflumizole 20 mg b.i.d. for four days followed by 20 mg daily for six days (Group II)
Number of subjects: 10
Study 2951260 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 10
Study 31839325 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke impact domain-mood
Number of subjects: 100
Study 31839325 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke impact domain-fatigue
Number of subjects: 100
Study 28750937 — intervention group
Group type: EXPERIMENTAL
Intervention: 60ml of castor oil
Number of subjects: 81
Study 28750937 — intervention group
Group type: COMPARATOR
Intervention: 60ml of sunflower oil (control)
Number of subjects: 81
Study 27397664 — intervention group
Group type: EXPERIMENTAL
Intervention: Suvorexant 20/15 mg
Number of subjects: 1260
Study 27397664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1260
Study 24477032 — intervention group
Group type: EXPERIMENTAL
Intervention: 0PEEP
Number of subjects: 75
Study 24477032 — intervention group
Group type: EXPERIMENTAL
Intervention: 5PEEP
Number of subjects: 75
Study 24477032 — intervention group
Group type: EXPERIMENTAL
Intervention: 10PEEP
Number of subjects: 75
Study 24477032 — intervention group
Group type: COMPARATOR
Intervention: 5PEEP and 10PEEP
Number of subjects: 75
Study 23636236 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc (20 mg elemental zinc/d)
Number of subjects: 550
Study 23636236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 550
Study 20632667 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine 5 mg (group A; n = 31)
Number of subjects: 62
Study 20632667 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine 100 ug (group B; n = 31)
Number of subjects: 62
Study 20632667 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 62
Study 18373147 — intervention group
Group type: EXPERIMENTAL
Intervention: Online screening survey via patient internet portal
Number of subjects: 4017
Study 16801301 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum intervention with tailored, brief feedback to promote positive attitudes and accurate knowledge about NRT.
Number of subjects: 97
Study 12922081 — intervention group
Group type: EXPERIMENTAL
Intervention: Low initial IgG antibody concentrations against pertussis toxin
Number of subjects: 627
Study 12922081 — intervention group
Group type: EXPERIMENTAL
Intervention: No previous history of pertussis vaccination or disease
Number of subjects: 627
Study 12922081 — intervention group
Group type: EXPERIMENTAL
Intervention: Less than 14 days of cough
Number of subjects: 627
Study 10804023 — intervention group
Group type: EXPERIMENTAL
Intervention: Low calcium dialysate (2.25 mEq/liter or 2.5 mEq/liter)
Number of subjects: 33
Study 10804023 — intervention group
Group type: COMPARATOR
Intervention: Regular calcium dialysate (3.0 mEq/liter or 3.5 mEq/liter)
Number of subjects: 33
Study 10804023 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined study values at 0, 6, and 12 months
Number of subjects: 33
Study 8642163 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mcg HBs vaccine (Recombivax, Merck, Sharp and Dohme)
Number of subjects: 29
Study 8642163 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mcg PreS2 + S vaccine
Number of subjects: 29
Study 8642163 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 mcg PreS2 + S vaccine
Number of subjects: 29
Study 8642163 — intervention group
Group type: EXPERIMENTAL
Intervention: Fourth vaccination (for poor and non-responders)
Number of subjects: 29
Study 1737453 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral nutrition plus human albumin 25 g/L as a continuous infusion
Number of subjects: 30
Study 1737453 — intervention group
Group type: COMPARATOR
Intervention: Parenteral nutrition (control)
Number of subjects: 30
Study 3896964 — intervention group
Group type: EXPERIMENTAL
Intervention: +cyanidanol-3 (3 g daily)
Number of subjects: 40
Study 3896964 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 29302609 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Lifestyles Programme (HeLP) intervention delivered over 1 year, including physical activity workshops, education sessions, drama sessions, and parental support.
Number of subjects: 1324
Study 29302609 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1324
Study 27371884 — intervention group
Group type: EXPERIMENTAL
Intervention: Epi-Care (group 1A, n = 14)
Number of subjects: 43
Study 27371884 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio baby monitor (group 1B, n = 13)
Number of subjects: 43
Study 27371884 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring group (group 1)
Number of subjects: 43
Study 27371884 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 2, n = 16)
Number of subjects: 43
Study 23891422 — intervention group
Group type: EXPERIMENTAL
Intervention: Los Angeles Unified School District's food-and-beverage standards of 2004
Number of subjects: 0
Study 22399076 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS group therapy
Number of subjects: 48
Study 22399076 — intervention group
Group type: COMPARATOR
Intervention: EDU session
Number of subjects: 48
Study 20878013 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow mononuclear cell (BMMC) transplantation
Number of subjects: 24
Study 18448233 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (physiotherapist-guided pelvic floor muscle training)
Number of subjects: 85
Study 18448233 — intervention group
Group type: COMPARATOR
Intervention: Group B (pelvic floor muscle training without physiotherapist guidance)
Number of subjects: 85
Study 18578276 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive educational guidelines
Number of subjects: 72
Study 15060238 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo care (KC) shortly after delivery for 1 hour
Number of subjects: 47
Study 15060238 — intervention group
Group type: COMPARATOR
Intervention: No-treatment standard care (control group)
Number of subjects: 47
Study 11751716 — intervention group
Group type: COMPARATOR
Intervention: Hypertensive individuals
Number of subjects: 228
Study 11751716 — intervention group
Group type: EXPERIMENTAL
Intervention: Blacks
Number of subjects: 228
Study 9538712 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical significance in nursing research
Number of subjects: 0
Study 9538712 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative research and informal knowledge
Number of subjects: 0
Study 9538712 — intervention group
Group type: EXPERIMENTAL
Intervention: High-quality research
Number of subjects: 0
Study 9538712 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical relevance
Number of subjects: 0
Study 7685684 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 50mg/misoprostol 200 micrograms
Number of subjects: 372
Study 7685684 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 50mg
Number of subjects: 372
Study 3545461 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Dopa plus benserazide
Number of subjects: 16
Study 3545461 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 16
Study 3545461 — intervention group
Group type: EXPERIMENTAL
Intervention: Piribedil
Number of subjects: 16
Study 3545461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31808298 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose SAR425899 (0.03, 0.06 and 0.09 mg)
Number of subjects: 36
Study 31808298 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose SAR425899 (0.06, 0.12 and 0.18 mg)
Number of subjects: 36
Study 31808298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 31808298 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose SAR425899
Number of subjects: 36
Study 31808298 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose SAR425899
Number of subjects: 36
Study 30183438 — intervention group
Group type: EXPERIMENTAL
Intervention: New adalimumab formulation
Number of subjects: 0
Study 30183438 — intervention group
Group type: COMPARATOR
Intervention: Existing adalimumab formulation
Number of subjects: 0
Study 30183438 — intervention group
Group type: COMPARATOR
Intervention: Influenza vaccine
Number of subjects: 0
Study 28922422 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified follow-up protocol
Number of subjects: 0
Study 25584730 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness inspired protocol delivered by an Android application for smartphones
Number of subjects: 56
Study 25584730 — intervention group
Group type: COMPARATOR
Intervention: Listening to relaxing music
Number of subjects: 56
Study 25584730 — intervention group
Group type: COMPARATOR
Intervention: Waiting list group
Number of subjects: 56
Study 22909998 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 Gy plus capecitabine
Number of subjects: 565
Study 22909998 — intervention group
Group type: COMPARATOR
Intervention: 50 Gy plus capecitabine and oxaliplatin
Number of subjects: 565
Study 21920036 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 0
Study 21920036 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride
Number of subjects: 0
Study 19878390 — intervention group
Group type: COMPARATOR
Intervention: Retin-OX+ lotion applied on one side of the face for 8 weeks
Number of subjects: 30
Study 16306324 — intervention group
Group type: EXPERIMENTAL
Intervention: High-functioning ASD group
Number of subjects: 14
Study 16306324 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 14